Open Access Open Access  Restricted Access Subscription Access

An Essential Parameters of Tacrolimus Include Objectives, Symptoms, Mechanism of Action, Administration, Adverse Effects, Contraindications, Monitoring, Toxicity and Enhancing Healthcare Team Outcomes

Muralinath E., Sony Sharlet E., Madhavi Latha C., Ramadevi Ch., Sheethal U., Guruprasad M., Karthik Jayanth Y., Renuka U.

Abstract


A key component of contemporary immunosuppressive therapy, tacrolimus is a drug used to prevent and treat solid-organ transplant rejection. The indications, mode of action, and contraindications of tacrolimus as a useful medication for immunosuppressive therapy are covered in this exercise. The activity explains toxicity, adverse event profiles, FDA-issued box warnings, and important factors like dosage, monitoring, and pertinent drug interactions. Comprehending the complex pharmacology of tacrolimus enables medical practitioners to customize therapy regimens, particularly for specific individuals. A thorough understanding of tacrolimus provides medical practitioners with a scientific basis for the practical management of transplant immunosuppression and associated conditions, facilitating well-informed decision-making, optimizing dosage schedules, and reducing side effects in order to maintain therapeutic efficacy.

With a focus on safe administration, therapeutic medication monitoring, and early toxicity detection, the participant learns how to apply evidence-based knowledge of tacrolimus to actual clinical decision-making. This activity promotes patient outcomes and care standards by fostering teamwork and providing healthcare personnel with the necessary information and resources for providing exceptional patient care during tacrolimus administration. The emphasis is on empowering healthcare professionals and highlighting the essential role of the interprofessional healthcare team regarding the management of tacrolimus therapy for transplant and autoimmune patients. Collaboration among pharmacists, clinicians, and other specialists increases patient outcomes by promoting communication, coordinating monitoring strategies, decreasing medication errors, and ensuringg individualized, patient-centered care that supports long-term treatment success.


Full Text:

PDF

References


Pitre, T., Gurupatham, S., Desai, K., Binnie, M., Martinu, T., Juvet, S., & Zeraatkar, D. (2025). Tacrolimus versus cyclosporine immunosuppression in lung transplantation: A systematic review and meta-analysis. BMJ Open Respiratory Research, 12(1). https://doi.org/10.1136/bmjresp-2024-002905

Erdman, J., Wolfram, J., Nimke, D., Croy, R., Wang, X., Weaver, T., Schladt, D., & Fitzsimmons, W. E. (2023). Pediatric lung transplant outcomes based on immunosuppressive regimen at discharge: Retrospective cohort study using real-world evidence from the US Scientific Registry of Transplant Recipients. Transplantation Proceedings, 55(7), 1692–1705. https://doi.org/10.1016/j.transproceed.2023.05.017

Suilik, H. A., Al-Shammari, A. S., Soliman, Y., Suilik, M. A., Naeim, K. A., Nawlo, A., & Abuelazm, M. (2024). Efficacy of tacrolimus versus cyclosporine after lung transplantation: An updated systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials. European Journal of Clinical Pharmacology, 80(12), 1923–1935. https://doi.org/10.1007/s00228-024-03766-0

Dellgren, G., Lund, T. K., Raivio, P., Leuckfeld, I., Svahn, J., Holmberg, E. C., Olsen, P. S., Halme, M., Fiane, A., Lindstedt, S., Riise, G. C., & Magnusson, J. (2024). Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): A multicentre randomised controlled trial. The Lancet Respiratory Medicine, 12(1), 34–44. https://doi.org/10.1016/S2213-2600(23)00395-0

Hamilton, B. K., Rybicki, L. A., Li, H., Lucas, T., Corrigan, D., Kalaycio, M., Sobecks, R., Hanna, R., Rotz, S. J., Dean, R. M., Gerds, A. T., Jagadeesh, D., Brunstein, C., Sauter, C. S., Copelan, E. A., & Majhail, N. S. (2023). Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention. Blood Advances, 7(16), 4505–4513. https://doi.org/10.1182/bloodadvances.2023010033

Naniwa, T., & Kajiura, M. (2025). Long-term effectiveness and safety of methotrexate-tacrolimus combination therapy versus methotrexate monotherapy in reducing rheumatoid arthritis flares after TNF inhibitor discontinuation: A retrospective cohort study. BMC Rheumatology, 9(1), 39. https://doi.org/10.1186/s41927-025-00452-4

Jiang, A., Hu, Q., Wang, Z., & Wu, F. (2025). Efficacy and safety of tacrolimus therapy in patients with juvenile myasthenia gravis: A single-arm meta-analysis. Pediatric Neurology, 166, 32–38. https://doi.org/10.1016/j.pediatrneurol.2025.03.008

Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Barnes, E. L., & Long, M. D. (2025). ACG clinical guideline update: Ulcerative colitis in adults. The American Journal of Gastroenterology, 120(6), 1187–1224. https://doi.org/10.14309/ajg.0000000000003376

Chu, D. K., Schneider, L., Asiniwasis, R. N., Boguniewicz, M., De Benedetto, A., Ellison, K., Frazier, W. T., Greenhawt, M., Huynh, J., Kim, E., LeBovidge, J., Lind, M. L., Lio, P., Martin, S. A., O'Brien, M., Ong, P. Y., Silverberg, J. I., Spergel, J. M., Wang, J., ... AAAAI/ACAAI Joint Task Force on Practice Parameters. (2024). Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Annals of Allergy, Asthma & Immunology, 132(3), 274–312. https://doi.org/10.1016/j.anai.2023.11.024

Ruzicka, T., Assmann, T., & Lebwohl, M. (2003). Potential future dermatological indications for tacrolimus ointment. European Journal of Dermatology, 13(4), 331–342.

Su, Z., Hu, J., Cheng, B., & Tao, X. (2022). Efficacy and safety of topical administration of tacrolimus in oral lichen planus: An updated systematic review and meta-analysis of randomized controlled trials. Journal of Oral Pathology & Medicine, 51(1), 63–73. https://doi.org/10.1111/jop.13232

Pluta, N. A., Kemp, T. L., & Rivard, S. C. (2025). Treatment considerations for pyoderma gangrenosum after reduction mammoplasty in an unsuspecting patient demographic. Plastic and Reconstructive Surgery – Global Open, 13(1), e6448. https://doi.org/10.1097/GOX.0000000000006448

Duplaine, A., Tannous, J., Seneschal, J., Ezzedine, K., Passeron, T., Dupin, N., Quereux, G., Beylot-Barry, M., Chosidow, O., Guillot, B., & Centre of Evidence of Société Française de Dermatologie. (2025). Value of tacrolimus 0.1% in the treatment of vitiligo in the era of targeted therapy. Annales de Dermatologie et de Vénéréologie, 152(2), 103352. https://doi.org/10.1016/j.annder.2024.103352

Salem, G., Ding, K., Sakuraba, A., & Cohen, R. (2021). Role of topical tacrolimus in the management of proctitis, perianal manifestations in Crohn's disease, and chronic pouchitis: A systematic review. Journal of Investigative Medicine, 69(4), 796–803. https://doi.org/10.1136/jim-2020-001642

Damião, A. O. M. C., de Azevedo, M. F. C., Carlos, A. S., Wada, M. Y., Silva, T. V. M., & Feitosa, F. C. (2019). Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World Journal of Gastroenterology, 25(9), 1142–1157. https://doi.org/10.3748/wjg.v25.i9.1142

Thomson, A. W., Bonham, C. A., & Zeevi, A. (1995). Mode of action of tacrolimus (FK506): Molecular and cellular mechanisms. Therapeutic Drug Monitoring, 17(6), 584–591. https://doi.org/10.1097/00007691-199512000-00006

Sharma, V. K., Niraula, A., Tuladhar, E. T., Dubey, R. K., Bhattarai, A., Raut, M., Kadel, A., Kharal, N., Sapkota, S., & Pokhrel, P. (2025). Tacrolimus (FK-506) levels determined by two different chemiluminescence immunoassay-based analytical methods: A comparative cross-sectional study. Medicine, 104(39), e44895. https://doi.org/10.1097/MD.0000000000044895

Henkel, L., Jehn, U., Thölking, G., & Reuter, S. (2023). Tacrolimus—Why pharmacokinetics matter in the clinic. Frontiers in Transplantation, 2, 1160752. https://doi.org/10.3389/frtra.2023.1160752

Marfo, K., Altshuler, J., & Lu, A. (2010). Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients. Pharmaceutics, 2(3), 291–299. https://doi.org/10.3390/pharmaceutics2030291

Piletta-Zanin, A., De Mul, A., Rock, N., Lescuyer, P., Samer, C. F., & Rodieux, F. (2021). Case report: Low hematocrit leading to tacrolimus toxicity. Frontiers in Pharmacology, 12, 717148. https://doi.org/10.3389/fphar.2021.717148


Refbacks

  • There are currently no refbacks.